Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals — Investor Presentation (January 2024)

53 slides from Marinus Pharmaceuticals's investor presentation, Jan 4, 2024

  1. Slide 1: Corporate Presentation January 2024

    Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder Corporate Presentation January 2024

  2. Slide 2: Forward-looking statements

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe ha

  3. Slide 3: Ganaxolone Development Pipeline

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Ganaxolone Development Pipeline 3 Ganaxolone is a positive allosteric GABAA receptor modulator with a well-defined MOA designed to treat patients suffering from seizure disorders. Ganaxolone is designed to modulate both synaptic and extrasynaptic

  4. Slide 4: Ganaxolone U.S. Market Opportunity

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I 4 ¹Symonds et al. Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort. Brain. 2019 Aug 1;142(8):2303-2318. ²Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372:657–6

  5. Slide 5: ZTALMY Marigold Clinical Data & Commercial Launch

    ZTALMY® (ganaxolone) oral suspension CV Marigold Clinical Data & Commercial Launch Not for promotional use

  6. Slide 6: Marigold Open Label Extension Data

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I 6 Reduction in monthly major motor seizure frequency through 2 years of the OLE* Patients who remained in the clinical trial at 2 years experienced sustained reduction in MMSF1 ► Following the pivotal trial, 88 out of 101 patients entered an open-

  7. Slide 7: ZTALMY Performance Metrics

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I ZTALMY® Performance Metrics 7 Preliminary U.S. net product revenue of $6.5M-$6.7M for the fourth quarter of 20231 More than 165 patients active on therapy at the end of 2023 U.S. net product revenue of $32M- $34M expected for the fiscal year 2024

  8. Slide 8: A Comprehensive Commercial Strategy to Grow the ZTALMY Brand

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I A Comprehensive Commercial Strategy to Grow the ZTALMY® Brand Patient identification Activate the caregiver community Focused education to HCPs to establish ZTALMY as the standard of care for CDD seizure management Continuously enhance the patient

  9. Slide 9: Rare Epilepsies Oral Ganaxolone Pipeline

    Rare Epilepsies Oral Ganaxolone Pipeline

  10. Slide 10: Tuberous Sclerosis Complex

    Tuberous Sclerosis Complex “Many individuals with TSC continue to experience uncontrolled seizures despite a cocktail of multiple antiepileptic drugs. Because new options are always needed, the TSC community welcomes clinical evaluation of new epilepsy treatments” - Kari Luther Rosbeck, President &

  11. Slide 11: Tuberous Sclerosis Complex (TSC)

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I 11 Tuberous Sclerosis Complex (TSC) CAUSE • Defect or mutation of TSC1 and/or TSC2 genes INCIDENCE • ~1 in 6,000 live births1 COMMON SYMPTOMS • Seizures, cognitive impairment, behavioral difficulties, skin/kidney/lung abnormalities, etc EPILEPSY I

  12. Slide 12: TSC Phase 2 Trial Results

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I TSC Phase 2 Trial Results 12 * -200 -100 -80 -60 -40 -20 0 20 40 60 80 100 Percent reduction in TSC-associated seizure frequency =median 16.6% Secondary and Exploratory Analyses Primary Endpoint Results: 16.6% median reduction in TSC-associated se

  13. Slide 13: Phase 3 Protocol Refinements Informed by Phase 2

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Phase 3 Protocol Refinements Informed by Phase 2 13 Phase 3 Slower titration initially, designed to optimize tolerability and improve efficacy No (n=6) Yes (n=17) 0 5 10 15 20 25 30 Somnolence-related AE Percentreduction in TSC-associated seizure

  14. Slide 14: Phase 3 Trial Overview

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Phase 3 Trial Overview 14 ► Enrollment: ~128 patients, targeting sites in the U.S., Western Europe, Canada, Israel, Australia and China • 90% powered to detect a 25% treatment difference • Statistical significance could be achieved with a treatmen

  15. Slide 15: TrustTSC Patient Experience and Demographics

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I TrustTSC Patient Experience and Demographics 15 *These are preliminary data as of August 2023 and may not be representative of demographics of patients and discontinuation rates upon completion of the TrustTSC Trial Age (mean [min-max]) 15 [2-39]

  16. Slide 16: Addressable Patient Population

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Addressable Patient Population ~2,000 9.6-11k 40% Highly Refractory4 CDD Patients5 TSC Highly Refractory CDD Patients TSC Epileptic TSC Prevalence TSC Refractory TSC CDD 24-28k 60-65% Refractory3 40-43k 80-85% Epileptic2,3 50,000 1/6000 incidence1

  17. Slide 17: Leverage of Existing ZTALMY Infrastructure to TSC

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Leverage of Existing ZTALMY® Infrastructure to TSC Expected to Yield Significant Return with Modest Expansion 17 17 TSC COMMERCIAL INFRASTRUCTURE Modest increase in field force MARKETING STRATEGY Distinct TSC positioning EXPANDED TARGETS 80% overl

  18. Slide 18: Second Generation Product Development

    Second Generation Product Development

  19. Slide 19: Second Generation Ganaxolone Goals

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Second Generation Ganaxolone 19 Goals Target Oral Pharmacokinetic Profile Increase efficacy Consistent delivery to achieve target plasma concentration Improve tolerability Optimize PK profile to reduce Cmax-related adverse effects Reduce dosing fr

  20. Slide 20: Next Steps: Prodrug and Ganaxolone Reformulation

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Next Steps: Prodrug and Ganaxolone Reformulation 20 Ganaxolone Prodrug Oral prodrug candidate selected Goals: • Optimize PK parameters for efficacy, tolerability and dosing frequency • Increase absorption (oral), solubility (IV) Preclinical IND-en

  21. Slide 21: Phase 1 Single Ascending Dose (SAD) Study

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Phase 1 Single Ascending Dose (SAD) Study 21 21 Mean Cmax (ng/mL) Mean AUC0-t (h*ng/mL) 41% 31% 38% 18% 18% 14% Study design Ganaxolone reformulation demonstrated linear kinetics at single doses from 100-1200 mg • Single dose PK study in healthy a

  22. Slide 22: Acute Seizure Disorders Intravenous (IV) Ganaxolone Pipeline

    Acute Seizure Disorders Intravenous (IV) Ganaxolone Pipeline

  23. Slide 23: Status Epilepticus

    Status Epilepticus

  24. Slide 24: Status Epilepticus Overview

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Status Epilepticus Overview 24 Status Epilepticus = Condition resulting from either the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms which lead to: • abnormally prolonged seizures (after time p

  25. Slide 25: Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I 25 Pharmacokinetics/Pharmacodynamics Well Suited for Acute SE Treatment Experimental PK – plasma and brain1 Brain and plasma concentration after ganaxolone 3 mg/kg IM in mice Human PD – EEG changes2 EEG bispectral index in healthy volunteers follo

  26. Slide 26: Strategic Approach to SE Clinical Development

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Strategic Approach to SE Clinical Development 26 1. DeLorenzo RJ Pellock JM Towne AR Boggs JG. Epidemiology of status epilepticus. J Clin Neurophysiol. 1995; 12: 316-325 2. Kapur et al. Randomized Trial of Three Anticonvulsant Medications for Stat

  27. Slide 27: Refractory Status Epilepticus Trial (RSE) Design

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Treatment Period Loading Dose Maintenance Taper 27 Phase 2 Refractory Status Epilepticus Trial (RSE) Design • Diagnosis of convulsive or non-convulsive SE • Failed at least one 2nd line IV AED but had not progressed to 3rd line IV anesthetics Bolu

  28. Slide 28: Phase 2 Trial Results Demonstrated Rapid Onset And Durability of Effect

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I 28 Phase 2 Trial Results Demonstrated Rapid Onset And Durability of Effect Data presented at AES 2019 AEDs – antiepileptic drugs Cohort No escalation to IV anesthetics within 24 hours from infusion initiation (Primary Endpoint) Status-free through

  29. Slide 29: PK/PD Relationship and Rationale for Target Dose

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I PK/PD Relationship and Rationale for Target Dose 29 29 PK model estimations Vaitkevicius H et al. Intravenous ganaxolone for the treatment of refractory status epilepticus: Results from an open-label, dose-finding, phase 2 trial. Epilepsia. 2022 S

  30. Slide 30: RAISE: Phase 3 Trial in Refractory Status Epilepticus

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Patient Population Study Treatment RAISE: Phase 3 Trial in Refractory Status Epilepticus 30 *SE, status epilepticus; SRSE, super refractory status epilepticus; IV, intravenous; ASM, antiseizure medication; IV ASMs: fosphenytoin/phenytoin, levetira

  31. Slide 31: Baseline Characteristics of the RAISE Trial

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Baseline Characteristics of the RAISE Trial* 31 Phase 2 RSE Study (17 patients)1 Phase 3 RAISE Study *This is preliminary RAISE data as of Sept. 2023 and may not be representative of demographics of patients upon full enrollment of the RAISE trial

  32. Slide 32: RAISE Endpoints and Interim Analysis

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I RAISE Endpoints and Interim Analysis 32 OTHER SECONDARY ENDPOINTS §Medications for the acute treatment of SE are defined as ASMs administered to abort ongoing SE or prevent imminent recurrence of SE based on clinical or EEG evidence. This definiti

  33. Slide 33: RAISE II: Phase 3 Trial in Refractory Status Epilepticus

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I RAISE II: Phase 3 Trial in Refractory Status Epilepticus 33 1 Kapur et al. Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus N Engl J Med 2019;381:2103-13. Benzodiazepine Administered IV AEDs (antiepileptic drugs) IV Anes

  34. Slide 34: Published Research Suggests Early Treatment Intervention May Improve Outcomes

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Published Research Suggests Early Treatment Intervention May Improve Clinical Outcomes 34 Status epilepticus (SE) duration ≥12 hours was an independent predictor of an unfavorable outcome at discharge in patients with post-stroke SE (OR 9.58 (1.97

  35. Slide 35: Approach to SRSE

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I ► Novel dosing approach and current EINDs • ↓Cmax but ↑ AUC + 3 month oral wean • Ganaxolone 833mg/day x 48h➛1,050mg/day x 168h • Captisol® 50gm/day ➛63gm/day Approach to SRSE 35 26 patients with SRSE treated to date with IV ganaxolone 14 with sim

  36. Slide 36: Super Refractory Status Epilepticus: Ganaxolone Experience to Date

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Super Refractory Status Epilepticus: Ganaxolone Experience to Date 36 New onset refractory status epilepticus (NORSE) Febrile illness-related epilepsy syndrome (FIRES) Lennox-Gastaut syndrome PCDH-19 related epilepsy Autoimmune encephalitis Herpes

  37. Slide 37: Building Commercial Infrastructure for Future IV Launches

    Building Commercial Infrastructure for Future IV Launches

  38. Slide 38: Roadmap to Success in the Hospital Market

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Roadmap to Success in the Hospital Market 38 38 Charting our own path to deliver a groundbreaking treatment for patients with refractory status epilepticus Market Segmentation & Targeting Robust Total Value Proposition Advanced analytics as a GPS

  39. Slide 39: Outcomes Deteriorate as RSE Progresses

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Outcomes Deteriorate as RSE Progresses Despite Intensive Levels of Care As SE progresses, healthcare resource utilization increases, but patient outcomes worsen IV anti-seizure meds Medically-induced coma with IV anesthetics Progression to ≥ 3 ASM

  40. Slide 40: Clinical and Healthcare Costs Associated with RSE

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Clinical and Healthcare Costs Associated with RSE 40 Utilization and Cost Outcomes Metric Cohort 1 (≤ 1 IV AED) Cohort 2 (> 1 IV AED) Cohort 3 (≥ 1 IV anesthetic) All Unique RSE patient encounter, N (%) 14,694 (33.4) 10,140 (23.1) 19,154 (43.5) 43

  41. Slide 41: Financial Update

    Financial Update

  42. Slide 42: Financial Overview

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Financial Overview 42 Analyst Coverage*: Cantor Fitzgerald: Charles C. Duncan, Ph.D. Cowen: Joseph Thome, Ph.D. H.C. Wainwright & Co: Douglas Tsao Jefferies: Andrew Tsai JMP Securities: Jason N. Butler, Ph.D. Ladenburg Thalmann: Michael Higgins Op

  43. Slide 43: Driving Global Access of ZTALMY (ganaxolone)

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Driving Global Access of ZTALMY® (ganaxolone) 43 Europe: Collaboration agreement with Orion Corporation for ganaxolone in CDD, TSC, RSE • Up to €90 million of development, commercial, and sales milestones1 ; tiered royalties in the low double-digi

  44. Slide 44: Intellectual Property

    Intellectual Property

  45. Slide 45: Multiple Layers Of Potential Protection

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Multiple Layers Of Potential Protection 45 Orphan drug designations for CDD and PCDH19 provide 7 and 10 years regulatory exclusivity in U.S. and EU, respectively. Orphan drug designation for SE provides 7 years regulatory exclusivity in U.S. U.S.

  46. Slide 46: Appendix

    Appendix (® MARINUS

  47. Slide 47: Phase 3 CDD Marigold Trial Data and Safety Summary

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I 47 Ganaxolone Placebo 0 10 20 30 40 Median Percent Reduction 28-day Frequency of Major Motor Seizures 30.7% 6.9% *Wilcoxon Rank-Sum Test **Hodges-Lehman Estimate of Median Dif erence Patients taking ganaxolone experienced a significant reduction i

  48. Slide 48: Average Ganaxolone Levels Correlate with Seizure Reduction

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Average Ganaxolone Levels Correlate with Seizure Reduction 48 • Logarithms of plasma ganaxolone level and percentage change in major motor seizure frequency were negatively correlated • Patients in the Medium and High ganaxolone level groups had a

  49. Slide 49: Details on Baseline Patient Characteristics for Phase 2 RSE Trial

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I 49 Details on Baseline Patient Characteristics for Phase 2 RSE Trial NCSE: Non-convulsive status epilepticus CSE: Convulsive status epilepticus LAC: Lacosamide LEV: Levetiracetam LOR: Lorazepam PHT: Phenytoin fPHT: Fosphenytoin VPA: Valproic Acid

  50. Slide 50: PK/PD Relationship and Rationale for Target Dose

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I 50 PK/PD Relationship and Rationale for Target Dose Modeled PK Curves for All Dose Groups High Dose Achieved Target Range ≥ 500 ng/mL for ~8 hours Only High Dose Provided Sustained Reduction (>80%) Throughout Entire Analysis Window Data presented

  51. Slide 51: RAISE Trial Sites Standard of Care Progression to IV Anesthesia

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I 51 RAISE Trial Sites Standard of Care Progression to IV Anesthesia ► Surveyed PI’s at selected RAISE Trial sites to learn more about their standard of care natural history progression to IV anesthesia following the failure of one versus more than

  52. Slide 52: RAISE Protocol Amended to Accelerate Enrollment

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I RAISE Protocol Amended to Accelerate Enrollment 52 Original Protocol Amended Protocol Patients excluded IF SE would NOT warrant anesthesia for the next 24 hours IV anesthesia would likely be next treatment if study drug (ganaxolone or placebo) doe

  53. Slide 53: Partnership and Non-Dilutive Funding Overview

    ©2024 Marinus Pharmaceuticals. All Rights Reserved I Partnership and Non-Dilutive Funding Overview 53 1 Subject to launch of Ztalmy and continued development and commercialization of ganaxolone 2 Subject to continued development and commercialization of ganaxolone 3 Additional funding of up to ~$18

Marinus Pharmaceuticals — Investor Presentation (January 2024) on 6ix